Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict
You may also be interested in...
Sequella CEO Carol Nacy On Partnering With Pfizer To Solve Multidrug-resistant TB
New drugs in development could help solve a looming global multidrug-resistant TB epidemic and anchor a new treatment regimen.
Asia Spotlight: AstraZeneca Shakeup Of China Business Unit Steers Focus Away From Generics To Innovative Drugs
AstraZeneca will dissolve its Broad Market business unit in China by merging it with primary care and move away from attracting business for branded generics in tier-3 rural markets, putting flesh on new CEO Pascal Soriot’s plan to focus on innovation.
AstraZeneca Shakeup Of China Business Unit Steers Focus Away From Generics To Innovative Drugs
AstraZeneca will dissolve its Broad Market business unit in China by merging it with primary care and move away from attracting business for branded generics in tier-3 rural markets, putting flesh on new CEO Pascal Soriot’s plan to focus on innovation.